Avalo Therapeutics, Inc.
AVTX
Jodie situation report
Avalo Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 21 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- AVTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AVTX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind AVTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
LLYEli Lilly and CompanypartnerNov 6, 2025 ▾
“AVTX-009 26 Table of Contents On March 27, 2024, Avalo obtained the rights to an anti-IL-1β mAb (AVTX-009), including the world-wide exclusive license from Eli Lilly and Company (“Lilly”) (the “Lilly License Agreement”), pursuant to its acquisition of AlmataB…”
Depended on by
ANROAlto Neuroscience, Inc.partnerNov 12, 2025 ▾
“License Agreement with Cerecor In May 2021, we entered into a patent and know-how license agreement, or the Cerecor Agreement, with Cerecor Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AVTX is currently a Follower in the organic co-movement group Oil & Gas and Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AVTX; it is not active in the latest market snapshot.